[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multi-cancer-early-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multi-cancer-early-screening":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100516988",false,"NCT06011694","The Jinling Cohort","A Prospective, Multicenter Cohort Study of the Multi-omics Liquid Biopsy MCED Test MERCURY in an Average Risk Chinese Population","Inclusion Criteria:\n\n1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent\n\nExclusion Criteria:\n\n1. Pregnant women;\n2. Individuals who have history of cancer or current diagnosis of cancer;\n3. Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;\n4. Individulas who have blood transfusion within 30 days prior to the blood draw;\n5. Individuals who have an acute infection or inflammation within 14 days prior to the blood draw;\n6. Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw;\n7. Individuals who will not be able to comply with the protocol procedures judged by researchers",true,"ALL","45 Years","75 Years",{"count":20,"type":21},15000,"ESTIMATED","OBSERVATIONAL","The Jinling Cohort is a prospective, multicenter cohort study in which 15,000 eligible individuals aged 45-75 in Nanjing China will be enrolled.",[25,26,27],"Cancer","Multi Cancer Early Screening","Liquid Biopsy",[29,30],"Early Detection of Cancer","MCED","RECRUITING","2023-08-23",{"date":34,"type":35},"2023-08-25","ACTUAL",{"date":37,"type":35},"2022-06-15",{"date":39,"type":21},"2027-05-15",{"name":41,"class":42},"Nanjing Shihejiyin Technology, Inc.","INDUSTRY",2,""]